Gene function and regulation
Xia Jian-Chuan's Laboratory
Summary
The laboratory of Jian-Chuan Xia, Ph.D. is within the State Key Laboratory of Oncology in South China. Xia's Lab is interested in gene function and regulation related to cancer and cancer immunotherapy study, with multidisciplinary approaches and tools including immuno histochemistery, Enzyme-linked immunosorbent assay (ELISA), Real-time quantitative RT-PCR, western blotting, flow cytometry , immune cell culture and electroporation and establish rat models of cancer.
Current Research
(1) Cancer genetics study
Tumor suppressor gene down-regulation may play an important role in tumor progress and development. We investigated several tumor suppressors such as ING2,TESTIN, BATF2, LZAP and BIN1, et al. expression in primary hepatocellular carcinoma(HCC) or gastric cancer (GC) and evaluated the relationship between these tumor suppressors’ expression and clinico pathological parameters of HCC or GC. Meanwhile, the prognostic value of these tumor suppressors for HCC or GC patients was also investigated. Furthermore, by examining in vitro proliferation, clone formation, motility, invasion and apoptosis of tumor cell lines, he also study the functional role of these tumor suppressors in the tumorigenesis of HCC or GC.
(2)Cancer Immunotherapy study
Immunotherapy is an important comprehensive treatment method for cancer patient. In Dr. Xia’s group, he investigated several immuno-effector cells such as cytokines induced killer cells (CIK), natural killer cells (NK), dendritic cells (DC) and DC-CIK for treatment of cancer patients. Furthermore, he investigated negative regulator such as SOCS1 and IDO for the function of DC, and studied whether silencing these negative regulators could enhance the anti-tumor immunity of DC. Moreover, he also investigated that DC/tumor fusion vaccines or genetic modified-DC vaccines for the treatment of cancer patients.
Contact Information
Jian-Chuan Xia, Ph.D.
Principle Investigator
Department of Cell therapy and Healthcare Research Center
Address
Rm#832, 651 Dongfeng Road East Guangzhou, Guangdong 510060, P.R. China
Office: (020)87343404
Email: xiajch@sysucc.org.cn
Publications
1. Zhao JJ, Pan QZ, Pan K, Weng DS, Wang QJ, Li JJ, Lv L, Wang DD, Zheng HX, Jiang SS, Zhang XF, Xia JC(Corresponding). Interleukin-37 Mediates the Antitumor Activity in Hepatocellular Carcinoma: Role for CD57+ NK Cells. Sci Rep. 2014 Jun 5;4:5177.
2. Pan K, Guan XX, Li YQ, Zhao JJ, Li JJ, Qiu HJ, Weng DS, Wang QJ, Liu Q, Huang LX, He J, Chen SP, Ke ML, Zeng YX, Xia JC(Corresponding). Clinical activity of adjuvant cytokine-induced killer cell (CIK) immunotherapy in patients with post-mastectomy triple-negative breast cancer patients. Clin Cancer Res. 2014 Jun 1;20(11):3003-11.
3. Keshari RP, Wang W, Zhang Y, Wang DD, Li YF, Yuan SQ, Qiu HB, Huang CY, Chen YM, Xia JC (Corresponding), Zhou ZW. Decreased Expression of the GATA3 Gene Is Associated with Poor Prognosis in Primary Gastric Adenocarcinoma. PLoS One. 2014 Feb 4;9(2):e87195
4. YangXB, Zhao JJ, Huang CY, Wang QJ, Pan K, Wang DD, Pan QZ, Jiang SS, Lv L, Gao X,Chen HW, Yao JQ, Zhi M, Xia JC (Corresponding). Decreased Expression of theFOXO3aGene Is Associated withPoor Prognosis in Primary Gastric Adenocarcinoma Patients. PLoS One. 2013 Oct 230;8(10): e78158
5. Pan QZ, Pan K, Zhao JJ, Chen JG, Li JJ, Lv L, WangDD, Zheng HX, Jiang SS, Zhang XF, Xia JC (Corresponding). Decreased expressionof interleukin-36α correlates with poor prognosis in hepatocellular carcinoma. Cancer ImmunolImmunother. 2013 Sep 6.
6. Lu L, Pan K, Zheng HX, Li JJ, Qiu HJ, Zhao JJ, WengDS, Pan QZ, Wang DD, Jiang SS, Chang AE, Li Q, Xia JC (Corresponding). IL-17Apromotes immune cell recruitment inhuman esophageal cancers and the infiltrating dendritic cells represent apositive prognostic marker for patient survival. J Immunother. 2013 Oct;36(8):451-8.
7. Pan K, Wang QJ, Liu Q, Zheng HX, Li YQ, Weng DS, LiJJ, Huang LX, He J, Chen SP, Ke ML, Zeng YX, Xia JC (Corresponding). Thephenotype of ex vivo generated cytokine-induced killer cells is associated withoverall survival in patients with cancer. TumourBiol. 2013 Aug 17.
8. Huang CY, Zhao JJ, Lv L, Chen YB, Li YF, Jiang SS,Wang W, Pan K, Zheng Y, Zhao BW, Wang DD, Chen YM, Yang L, Zhou ZW, Xia JC(Corresponding). Decreased Expression of AZGP1 Is Associated with PoorPrognosis in Primary Gastric Cancer. PLoSOne. 2013 Jul 23;8(7):e69155.
9. Pan K, Li YQ, Wang W, Xu L, Zhang YJ, Zheng HX, ZhaoJJ, Qiu HJ, Weng DS, Li JJ, Wang QJ, Huang LX, He J, Chen SP, Ke ML, Wu PH,Chen MS, Li SP, Xia JC (Corresponding), Zeng YX. The Efficacy of Cytokine-InducedKiller Cell Infusion as an Adjuvant Therapy for Postoperative HepatocellularCarcinoma Patients. Ann Surg Oncol. 2013 Jul 27.
10. Huang ZM, Li W, Li S, Gao F, Zhou QM, Wu FM, He N,Pan CC, Xia JC, Wu PH, Zhao M. Cytokine-induced killer cells in combinationwith transcatheter arterial chemoembolization and radiofrequency ablation forhepatocellular carcinoma patients. JImmunother. 2013 Jun;36(5):287-93.
11. Zhang F, Sun XF, Li YQ, Zhen ZJ, Zheng HX, Zhu J,Wang QJ, Lu SY, He J, Wang J, Pan K, Cai RQ, Chen Y, Weng DS, Sun FF, Xia JC(Corresponding). Safety of in vitro amplified HLA-haploidentical donor immunecell infusions for childhood malignancies. ChinJ Cancer. 2013 May 27. doi: 10.5732 / cjc.012.10298.
12. Zhao JJ, Pan K,Wang QJ, Xu ZD, Weng DS, Li JJ, Li YQ, Xia JC (Corresponding). Effect ofanti-asthma Chinese medicine Chuankezhi on the anti-tumor activity ofcytokine-induced killer cells. Chin J Cancer. 2013 Mar 8. doi:10.5732/cjc.012.10249.
13. Huang CY, Chen YM, Zhao JJ,Chen YB, Jiang SS, Yan SM, Zhao BW, Pan K, Wang DD, Lv L, Li YF, Wang W, ZhouZW, Xia JC (Corresponding). Decreased expression of transcription elongationfactor a-like 7 is associated with gastric adenocarcinoma prognosis. PLoS One. 2013;8(1):e54671.
14. Li JJ, Shan HB, Xu GL, He LJ, Xia JC. Submucosalsaline solution injection combined with endosonography for distinguishingbetween stages T1aand T1b ofearly esophageal cancer. GastrointestEndosc. 2013 Jan;77(1):159-60.
15. Li JJ, Pan K, Gu MF, Chen MS, Zhao JJ, Wang H, LiangXT, Sun JC, Xia JC (Corresponding). Prognostic value ofsoluble MICA levels in the serum of patients with advanced hepatocellularcarcinoma. Chin J Cancer. 2013Mar;32(3):141-8.
16. Li YF, Wang DD, Zhao BW, Wang W, Huang CY, Chen YM,Zheng Y, Keshari RP, Xia JC (Corresponding), Zhou ZW. High Level of COP1Expression is Associated with Poor Prognosis in Primary Gastric Cancer. Int J Biol Sci. 2012;8(8):1168-77.
17. Li YF, Wang DD, Zhao BW, Wang W, Yuan SQ, Huang CY,Chen YM, Zheng Y, Keshari RP, Xia JC (Corresponding), Zhou ZW. Poor prognosisof gastric adenocarcinoma with decreased expression of AHRR. PLoS One. 2012;7(8):e43555.
18. Wang DD, Chen YY, Pan K, Wang W, Chen SP, Chen JG,ZhaoJJ, Lv L, Pan QZ, Li YQ, Wang QJ, Huang LX, Ke ML, He J, Xia JC(Corresponding). Decreased Expression of the ARID1AGene Is Associated with Poor Prognosis in PrimaryGastric Cancer. PLoS One. 2012; 7(7):e40364
19. Zhao JJ, Pan K,Wang W, Chen JG, Wu YH, Lv L, Li JJ, Chen YB, Wang DD, Pan QZ, Li XD, Xia JC(Corresponding). The prognostic value of tumor-infiltrating neutrophils ingastric adenocarcinoma after resection. PLoS One. 2012;7(3):e33655.
20. Li JJ, Gu MF, Pan K, Liu LZ,Zhang H, Shen WX, Xia JC (Corresponding). Autologous Cytokine-InducedKiller Cell Transfusion in Combination with Gemcitabine plus Cisplatin RegimenChemotherapy for Metastatic Nasopharyngeal Carcinoma. J Immunotherapy. 2012 Feb-Mar;35(2):189-95.
21. Pan K, Liang XT, Zhang HK, Zhao JJ, Wang DD, Li JJ,Lian Q, Chang AE, Li Q, Xia JC (Corresponding).. Characterization of BIN1 as apotential tumor suppressor and prognostic marker in hepatocellular carcinoma. Mol Med. 2012 18:507-18.
22. Chen Y, Pan K, Li S, Xia J (Corresponding), Wang W,Chen J, Zhao J, Lü L, Wang D, Pan Q, Wang Q, Li Y, He J, Li Q. Decreasedexpression of V-set and immunoglobulin domain containing 1 (VSIG1) isassociated with poor prognosis in primary gastric cancer. J Surg Oncol. 2012 Sep 1;106(3):286-93.
23. Zhao JJ, Pan K, Li JJ, Chen YB, Chen JG, Lv L, WangDD, Pan QZ, Chen MS, Xia JC (Corresponding). Identification of LZAP as a NewCandidate Tumor Suppressor in Hepatocellular Carcinoma. PLoS One. 2011; 6(10): e26608.
24. Wang W, Lv L, Pan K, Zhang Y, Zhao JJ, Chen JG, ChenYB, Li YQ, Wang QJ, He J, Chen SP, Xia JC (Corresponding). Reduced expressionof transcription factor AP-2α is associated with gastric adenocarcinomaprognosis. PLoS One. 2011; 6(9):e24897.
25. Lv L, Pan K, Li XD, She KL, Zhao JJ, Wang W, ChenJG, Chen YB, Yun JP, Xia JC (Corresponding). The accumulation and prognosisvalue of tumor infiltrating IL-17 producing cells in esophageal squamous cellcarcinoma. PLoS One. 2011; 6(3):e18219.
26. Liang XT, Pan K, Chen MS, Li JJ, Wang H, Zhao JJ,Sun JC, Chen YB, Ma HQ, Wang QJ, Xia JC (Corresponding). Decreased expressionof XPO4 is associated with poor prognosis in hepatocellular carcinoma. J Gastroenterol Hepatol. 2011; 26(3):544-9
27. Ma H, Liang X, Chen Y, Pan K, Sun J, Wang H, Wang Q,Li Y, Zhao J, Li J, Chen M, Xia J (Corresponding). Decreased expression ofBATF2 is associated with a poor prognosis in hepatocellular carcinoma. Int J Cancer. 2011; 128(4): 771-7.
28. Chen JG, Xia JC (Corresponding), Liang XT, Pan K,Wang W, Lv L, Zhao JJ, Wang QJ, Li YQ, Chen SP, He J, Huang LX, Ke ML, Chen YB,Ma HQ, Zeng ZW, Zhou ZW, Chang AE, Li Q. Intratumoral Expression of IL-17 andIts Prognostic Role in Gastric Adenocarcinoma Patients. Int J Biol Sci. 2011; 7(1): 53-60.
29. Ma H, Weng D, Chen Y, Huang W, Pan K, Wang H, Sun J,Wang Q, Zhou Z, Wang H, Xia J (Corresponding). Extensive analysis of D7S486 inprimary gastric cancer supportsTESTIN as a candidate tumor suppressor gene. Mol Cancer. 2010; 9:190.
30. Pan K, Zhao JJ, Wang H, Li JJ, Liang XT, Sun JC,Chen YB, Ma HQ, Liu Q, Xia JC (Corresponding). Comparative analysis ofcytotoxic T lymphocyte response induced by dendritic cells loaded withhepatocellular carcinoma -derived RNA or cell lysate. Int J Biol Sci. 2010; 6(7): 639-48.
31. Sun JC, Liang XT, Pan K, Wang H, Zhao JJ, Li JJ, MaHQ, Chen YB, Xia JC (Corresponding). High expression level of EDIL3 inHCC predicts poor prognosis of HCCpatients. World J Gastroenterol. 2010; 16(36): 4611-5.
32. Wang QJ, Wang H, Pan K, Li YQ, Huang LX, Chen SP, HeJ, Ke ML, Zhao JJ, Li JJ, Sun JC, Liang XT, Ma HQ, Chen YB, Xia JC(Corresponding). Comparative study on anti-tumor immune response of autologouscytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), andsemi-allogeneic DC-CIK. Chin J Cancer.2010; 29(7): 641-8.
33. Sun JC, Pan K, Chen MS, Wang QJ, Wang H, Ma HQ, LiYQ, Liang XT, Li JJ, Zhao JJ, Chen YB, Pang XH, Liu WL,Cao Y, Guan XY, Lian QZ, Xia JC(Corresponding). Dendritic cells-mediated CTLs targeting hepatocellularcarcinoma stem cells. Cancer Biol Ther. 2010; 10(4): 368-75.
34. Ma H, Zhang Y, Wang Q, Li Y, He J, Wang H, Sun J,Pan K, Chen M, Xia J (Corresponding). Therapeutic safety and effects ofadjuvant autologous RetroNectin activated killer cell immunotherapy forpatients with primary hepatocellular carcinoma after radiofrequency ablation. Cancer Biol Ther. 2010; 9(11): 903-7.
35. Zhang H, Ma H, Wang Q, Chen M, Weng D, Wang H, ZhouJ, Li Y, Sun J, Chen Y, Liang X, Zhao J, Pan K, Wang H, Xia J (Corresponding).Analysis of loss of heterozygosity on chromosome 4q in hepatocellular carcinomausing high-throughput SNP array. OncolRep. 2010; 23(2): 445-55.
36. Zhou J, Weng D, Zhou F, Pan K, Song H, Wang Q, WangH, Wang H, Li Y, Huang L, Zhang H, Huang W, Xia JC (Corresponding).Patient-derived renal cell carcinoma cells fused with allogeneic dendriticcells elicit anti-tumor activity: in vitro results and clinical responses. Cancer Immunol. Immunother. 2009;58(10): 1587-97.
37. Pan K, Wang H, Liu W, Zhang H, Zhou J, Li J, Weng D,Huang W, Sun J, Liang X, Xia JC (Corresponding). The pivotal role of p38 andNF-κB signal pathways in the maturation of human monocyte-derived dendriticcells stimulated by streptococcal agent OK-432. Immunobiology 2009; 214(5): 350-358.
38. Zhang HK, Pan K, Wang H, Weng DS, Song HF, Zhou J,Huang W, Li JJ, Chen MS, Xia JC (Corresponding). Decreased Expression of Ing2Gene and Its Clinicopathological Significance in Hepatocellular Carcinoma. Cancer Lett. 2008; 261(2): 183-192.
39. Weng DS, Zhou J, Zhou QM, Zhao M, Wang QJ, Huang LX,Li YQ, Chen SP, Wu PH, Xia JC (Corresponding). Minimally Invasive TreatmentCombined with Cytokine-Induced Killer Cells Therapy Lower the Short-TermRecurrence Rates of Hepatocellular Carcinomas. J Immunother. 2008; 31(1): 63-71.
40. Ma HQ, Liang XT, Zhao JJ, Wang H, Sun JC, Chen YB,Pan K, Xia JC (Corresponding). Decreased expression of Neurensin-2 correlateswith poor prognosis in hepatocellular carcinoma. World J Gastroenterol. 2009; 15(38): 4844-8.
41. Wang H, Pan K, Zhang HK, Weng DS, Zhou J, Li JJ,Huang W, Song HF, Chen MS, Xia JC (Corresponding). Increased Polycomb-GroupOncogene Bmi-1 Expression Correlates with Poor Prognosis in HepatocellularCarcinoma. J Cancer Res Clin Oncol. 2008; 134(5): 535-541.
42. Pan K, Wang H, Chen MS, Zhang HK, Weng DS, Zhou J,Huang W, Li JJ, Song HF, Xia JC (Corresponding). Expression and prognosis roleof indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134(11):1247-1253
43. Weng DS, Li JT,Mai SJ, Pan ZZ, Feng BJ, Feng QS, Huang LX, Wang QJ,Li YQ, Yu XJ, Chen SP, He J, Xia JC (corresponding). Identification of a newtarget region on the long arm of chromosome7 ingastric carcinoma by loss of heterozygosity. World J Gastroenterol. 2006; 12(15):2437-2440.
44. Xia JC, Weng DS, Li JT, Qin HD,Mai SJ, Feng BJ, Fan Q, Feng QS,Huang LX, Yu XJ, Pan ZZ, Li YQ, Wang QJ, Zhan YQ, Chen SP, He J, Huang WL, WuPH, Zeng YX. Loss of heterozygosity analysis of a candidate gastric carcinomatumor suppressor locus at 7q31. CancerGenet Cytogenet. 2006; 166(2): 166-172.
45. Tanaka Y, Koido S, Xia JC （co-firster author）, Ohana M, Liu C,Cote GM, Sawyer DB, Calderwood S, Gong J. Development of Antigen-Specific CD8+Cytotoxic T Lymphocytes in MHC Class I-Deficient Mice through CD4 to CD8Conversion. J Immunol. 2004; 172:7848-7858.
46. Xia JC, Tanaka Y, Koido S, Liu C, Mukherjee P,Gendler SJ, Gong J. Prevention of spontaneous breast carcinoma by prophylacticvaccination with dendritic/tumor fusion cells. J Immunol. 2003; 170 (4): 1980-1986.